ClinicalTrials.gg
CompletedNCT05939947FEGATO-01Updated Dec 3, 2024

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

A Phase 1 interventional study of ALE.F02 and Placebo in Advanced Liver Fibrosis and Liver Cirrhosis, sponsored by Alentis Therapeutics AG. Completed at 6 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-12-03.

Sponsored by Alentis Therapeutics AG · Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Liver Cirrhosis with a site in Romania — 6 open to participants now, 6 under way, 1 of them phase 3. Liver Cirrhosis · Romania.

Enrollment
14th of 16
41 · median 223
Started
2023
with 3 others
Phase 1
2 of 22
none open now
Registered
16th of 22
by date
Lead sponsor
1 of 22
Alentis Therapeutics AG

Among the 22 studies in Liver Cirrhosis with a site in Romania, this one is the 14th largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2023, is one of 2 in phase 1, and was the 16th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

6 of the 22 studies in Liver Cirrhosis with a site in Romania are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Liver Cirrhosis with a site in Romania, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.

03

Conditions studied

  • Advanced Liver Fibrosis
  • Liver Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Principal Inclusion Criteria:

  • Outpatients between 18 and 80 years
  • Have been diagnosed with advanced liver fibrosis or mild cirrhosis attributable to NASH, ALD, or following a sustained virological response to treatment for
  • Have an ELF Score of at least 9.5 but no more than 13
  • Have stable hepatic impairment, defined as no change in disease status, and no previous liver cirrhosis decompensation episodes
  • Body weight within the range of 50.0 kg to 140.0 kg
  • Clinical frailty score \<6

Principal Exclusion Criteria:

  • score ≥7, as determined at screening
  • MELD score ≥12, as determined at screening
  • Estimated \<60 mL/min per the CKD-EPI creatinine-cystatin C equation
  • Current or history of HCC
  • Be suffering from or have symptoms of an acute or chronic infection
  • Have active hepatitis C infection
  • Other causes of liver disease including, but not limited to, , disorders drug-induced hepatotoxicity, Wilson's disease, iron overload, and alpha-1-antitryspin deficiency, based on medical history review.
  • Is a woman of
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    ALE.F02

    Patients will receive 3 doses of ALE.F02 administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses.

    Drug: ALE.F02

  • Placebo comparator
    Placebo

    Patients will receive 3 doses of matching placebo administered once every second week as a continuous intravenous (IV) infusion to a total of 3 doses.

    Drug: Placebo

Interventions

  • DrugALE.F02

    Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.

  • DrugPlacebo

    Continuous intravenous (IV) infusion administered once every second week to a total of 3 doses.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) profile of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis using noncompartmental analysis.

    Maximum Serum Concentration \[Cmax\]

    Time frame: Baseline to Day 14 and Day 29 to Day 72

  2. Pharmacokinetics (PK) profile of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis using noncompartmental analysis.

    Time of Maximum Serum Concentration \[Tmax\]

    Time frame: Baseline to Day 14 and Day 29 to Day 72

  3. Pharmacokinetics (PK) profile of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis using noncompartmental analysis.

    Area under the serum concentration versus time curve \[AUC0-tau, AUC0-inf\]

    Time frame: Baseline to Day 14 and Day 29 to Day 72

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis.

    Incidence of Treatment-Emergent Adverse Events assessed by CTCAE v5.0 criteria Incidence of Serious Adverse Events assessed by CTCAE v5.0 criteria

    Time frame: Baseline to Day 72

  2. Pharmacodynamic (PD) profile of ALE.F02 in patients with advanced liver fibrosis and/or with mild cirrhosis.

    Relative change (%) of serum levels of PRO-C3 between baseline and the EOT. Relative change (%) of serum levels of tissue inhibitor of matrix metalloproteinase \[TIMP1\] between baseline and the EOT. Relative change (%) of serum levels of hyaluronic acid between baseline and the EOT. Relative change (%) of serum levels of procollagen III amino-terminal peptide \[PIIINP\] between baseline and the EOT.

    Time frame: Baseline to Day 72

07

Study locations

6 sites
  • American Research Corporation
    San Antonio, Texas 78215, United States
  • APEX GmbH
    Munich, 81241, Germany
  • ARENSIA Exploratory Medicine S.R.L.
    Bucharest, 011665, Romania
  • ARENSIA Exploratory Medicine S.R.L. - Cluj-Napoca
    Cluj-Napoca, 400006, Romania
  • Summit Clinical Research
    Bratislava, 851 05, Slovakia
  • Summit Clinical Research
    Malacky, 90122, Slovakia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Oct 2024, 18 months.

Of 32 phase 1 interventional studies under Liver Cirrhosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 29. This study's 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2023
First posted
Jul 11, 2023
StartActual
Apr 1, 2023
Primary completionActual
Oct 30, 2024
CompletionActual
Oct 30, 2024
Last update
Dec 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05939947
Lead sponsor
Alentis Therapeutics AG
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Apr 1, 2023
Primary completion
Oct 30, 2024
Completion
Oct 30, 2024
Last update
Dec 3, 2024

Study contacts

Luigi Manenti, MD
study director · Alentis Therapeutics AG

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion